Name: Return on Equity (ROE)

Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.

Interpretation:
• In '2021', CTNM's return on equity was 40.9%, measuring profitability for shareholders. Industry average for Biotechnology: Pharmaceutical Preparations in '2021' stood at -45.2%.
• In '2022', CTNM's return on equity was 29.6%, measuring profitability for shareholders. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at -61.1%. Industry average declined by 15.9% from previous year.
• In '2023', CTNM's return on equity was -28.2%, measuring profitability for shareholders. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at -78.2%. Industry average declined by 17.2% from previous year.
• In '2024', CTNM's return on equity was -65.0%, measuring profitability for shareholders. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at -68.0%. Industry average increased by 10.2% compared to previous year.
Overall, CTNM's return on equity has been volatile but showed a downward trend over the past 4 years.

Formula: ROE = Net Income / Shareholders' Equity

Good Range: 10%-20% desirable for many industries.